Key Points

• Vaccination coverage among infants subject to the mandatory vaccination requirements in effect since 2018 is high in 2023 for vaccinations against diphtheria, tetanus, polio, pertussis, Haemophilus influenzae type b, hepatitis B, and pneumococcal disease; however, coverage remains insufficient for the measles, mumps, and rubella (MMR) vaccine, with regional coverage of 86.4% for the second dose of this vaccine. Given the current circulation of the measles virus, only a two-dose vaccination coverage of at least 95% is likely to interrupt transmission of the virus.

• 71.8% of infants aged 8 months in 2023 received at least one dose of the meningococcal B vaccine, representing an increase of more than 25 percentage points compared to the previous year. Vaccination coverage against meningococcal C is increasing among adolescents, but catch-up vaccination remains insufficient among young people aged 15 to 19, with a vaccination coverage rate of 44.4% in the region.

• 26.4% of infants born in 2023 received at least one dose of the rotavirus vaccine in the region. Significant disparities between departments are observed for this vaccination, which has been recommended since 2023.

• 54.3% of 15-year-old girls and 25.4% of 15-year-old boys began their HPV vaccination series in 2023. HPV vaccination coverage increased significantly in 2023, with a 6.7-point increase among girls and coverage that doubled among boys compared to 2022. HPV vaccination coverage remains far from the 80% target set by the 10-year cancer control strategy for 2030.

• At the conclusion of the first phase of the HPV vaccination campaign in middle school, as of December 31, 2023, it is estimated that approximately 54% of girls and 40% of boys aged 12 (born in 2011, mostly enrolled in 7th grade) received at least one dose of the HPV vaccine in middle school or at a private practice. An increase of 16 percentage points among girls and 15 percentage points among boys in vaccination coverage was observed between the start and end of the first phase of the campaign, although it is not yet possible to specify the proportion of this increase directly attributable to the campaign.

• Vaccination coverage against influenza, COVID-19, and shingles remains insufficient among at-risk individuals. Influenza vaccination coverage is declining during the 2023–2024 season among people under 65 with risk factors (25.8%) and those over 65 (53.3%). Vaccination coverage for the fall 2023 COVID-19 booster was 30.6% among those aged 65 and older. Less than 2% of people aged 65–74 were vaccinated against shingles in 2023.

• Vaccination coverage against pertussis among young mothers two months after childbirth is estimated at 73.2% in 2021.

• 83.7% of respondents in mainland France report being in favor of vaccination in general, a rate that remains broadly stable compared to previous years (84.6% in 2022 and 82.5% in 2021), and higher than previously observed levels.

• With the aim of informing and promoting vaccination among the public and healthcare professionals, Santé publique France provides a wide range of tools to promote vaccination.